3150+ Attendees
Our conference has attracted and served over 3150 participants, creating
valuable networking opportunities and collaborations
- First Round of Abstract Submission Deadline: December 29, 2025
- Pre Early Bird Registrations Ends: December 09, 2025
Vaccines Research & Development
International Conference on Vaccines Research & Development is a federally registered trademark (reg.no. 5226683) owned by USG United Scientific Group (A non-profit organization). Beware of fraudulent conferences mimicking the Official Vaccines R&D Conference.
- Call Now
- Send Email
-
Address
8105 Rasor Blvd, Suite 112, Plano, TX 75024, USA
Vaccines Research & DevelopmentTM
11th International Conference on
Vaccines Research & DevelopmentTM
November 9-11, 2026 | Boston, MA | Hybrid
International Conference on Vaccines Research &
Development is a federally registered trademark
(reg.no. 5226683) owned by USG United Scientific Group (A non-profit
organization). Beware of fraudulent conferences mimicking the Official Vaccines
R&D Conference.
Venue: Four Points by Sheraton Wakefield Boston Hotel & Conference Center
Why Choose Us!
The Prime Gathering for Global Vaccine R&D Community
1100 Speakers
Vaccines R&D has hosted and engaged with over 1100 distinguished speakers,
enriching our events with diverse expertise and insights
11 Years Experience
A decade of experience in conference organization, delivering seamlessly
executed events that foster knowledge sharing and networking excellence
The Highlighting Part Of Our Program
The conference explores a wide range of topics and sessions, delving into the following areas:
Technology & Delivery Platforms
mRNA, Vector-based, Nanoparticle vaccines, Adjuvants and Emerging technologies
RSV, Influenza, COVID-19
RSV, Influenza, COVID-19, Pneumococcal, Tuberculosis, Whooping cough
Vaccine Development
Preclinical studies, Clinical trials, Regulatory review, Manufacturing, Quality control, Post-market surveillance
Immune Characterization
Antibody production, Neutralization assays, Immune markers, Cytokine profiles, mAbs
New and Emerging
Zika, Ebola, Marburg, Lassa fever, Dengue
Bacterial and Viral
DTP, Pneumococcal, Meningococcal, MMR, Hepatitis, HPV, Chickenpox
Conjugate Vaccines
Recombinant, Polysaccharide, Subunit vaccines
Manufacturing and Regulatory
Antigen production, Formulation, QC, Scale-Up, Cold Chain management
Role of Adjuvants
Immune response, Duration of protection, Vaccine efficacy, Subunit vaccines
Cancer, HIV
Preventive, Therapeutic vaccines, Tumor antigens
Vaccine Safety
Preclinical testing, Adverse event reporting, Regulatory approval, Vaccine hesitancy
Clinical Trials
Phase I, II and III studies
Gallery
2025 Conference Highlights
Pre Early Bird Registration
$749
Academic
- Access to all talks and posters
- Conference material
- Hot buffet lunch, tea / coffee breaks
- WiFi in meeting rooms
- Networking and drinks
$849
Federal
- Access to all talks and posters
- Conference material
- Hot buffet lunch, tea / coffee breaks
- WiFi in meeting rooms
- Networking and drinks
$899
Biotech & Pharma
- Access to all talks and posters
- Conference material
- Hot buffet lunch, tea / coffee breaks
- WiFi in meeting rooms
- Networking and drinks
$399
Virtual
- Access to all talks and posters
- Conference material
- Hot buffet lunch, tea / coffee breaks
- WiFi in meeting rooms
- Networking and drinks
Conference Overview
Unveiling the Most Recent Advancements in Vaccines R&D
The Vaccines R&D 2026 conference is set to serve as a dynamic platform,
fostering interdisciplinary collaboration at the cutting edge of accelerated and essential
vaccine research. Across a span of three days, distinguished speakers from around the world,
representing industry, academia, federal bodies, and regulatory agencies, will share
groundbreaking advancements, address contemporary challenges, and provide inspirational
insights and innovative lessons gained during the vaccine development process.
Companies Participated
